Liver and Fat Regulation in Overweight Adolescent Girls (APPLE)
Primary Purpose
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Byetta 5Mcg Pen Injection
Sponsored by
About this trial
This is an interventional other trial for Hepatic Steatosis
Eligibility Criteria
Inclusion Criteria:
- Females
- 2 years post-menarche
- BMI percentile >90%
Exclusion Criteria:
- Type 2 diabetes
- Anemia
- Liver disease
- Medications known to effect insulin sensitivity
- Cause of oligomenorrhea or hirsutism other than PCOS,
- >3 hours a week of moderate exercise.
Sites / Locations
- University of Colorado Anshutz Medical Campus/Children's Hospital Colorado
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
No Intervention
No Intervention
No Intervention
No Intervention
Arm Label
PCOS, medication naive + Byetta
Control
PCOS medication naive
PCOS on COCPs
PCOS on metformin
Arm Description
PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
Up to 25 girls without PCOS
Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
Outcomes
Primary Outcome Measures
Hepatic glucose release
Hepatic glucose release will be measured by the rate of appearance of a glucose tracer.
Secondary Outcome Measures
Hepatic phosphate concentrations
Hepatic phosphate relative concentrations will be measured with 31 phosphorus magnetic resonance spectroscopy
Rates of lipolysis
Rate of lipolysis will be measured by the rate of appearance of a glycerol tracer.
Hepatic Fat Fraction
Amount of fat in the liver measured by MRI and calculated via the Dixon method as the proton density hepatic fat fraction, which ranges from 0-75%. Greater than 5% is considered extra fat in the liver.
Hepatic de novo lipogenesis
Hepatic de novo lipogenesis will be measured by with an acetate tracer.
Full Information
NCT ID
NCT02157974
First Posted
June 4, 2014
Last Updated
August 15, 2023
Sponsor
University of Colorado, Denver
Collaborators
National Center for Advancing Translational Sciences (NCATS)
1. Study Identification
Unique Protocol Identification Number
NCT02157974
Brief Title
Liver and Fat Regulation in Overweight Adolescent Girls
Acronym
APPLE
Official Title
Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
August 2014 (Actual)
Primary Completion Date
December 2022 (Actual)
Study Completion Date
December 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
National Center for Advancing Translational Sciences (NCATS)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Women with polycystic ovarian syndrome (PCOS) have increased rates of hepatic steatosis compared to weight similar women with regular menses. It is unclear if this is related to high testosterone or insulin resistance. The investigators will assess hepatic glucose release, rates of lipolysis and hepatic de novo lipogenesis in the fasted and postprandial state to determine if alterations in the processes contribute to hepatic steatosis. Participants will be overweight, sedentary girls with or without PCOS. Those with PCOS will either be medication naive, or must be taking metformin or combined oral contraceptives (COCPs) for a period of at least 6 months prior to study procedures.
Detailed Description
Hepatic glucose release will be assessed with a stable isotope glycerol tracer, lipolysis with a glycerol tracer, and hepatic de novo lipogenesis with an acetate tracer. Data will be collected fasting and after a glucose challenge. The degree of hepatic steatosis and abdominal fat partitioning will be assessed with Magnetic Resonance Imaging (MRI), and total body composition with Dual-energy X-ray absorptiometry (DEXA).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
7. Study Design
Primary Purpose
Other
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
92 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PCOS, medication naive + Byetta
Arm Type
Experimental
Arm Description
PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Up to 25 girls without PCOS
Arm Title
PCOS medication naive
Arm Type
No Intervention
Arm Description
Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
Arm Title
PCOS on COCPs
Arm Type
No Intervention
Arm Description
Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
Arm Title
PCOS on metformin
Arm Type
No Intervention
Arm Description
Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
Intervention Type
Drug
Intervention Name(s)
Byetta 5Mcg Pen Injection
Other Intervention Name(s)
Exenatide
Intervention Description
10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
Primary Outcome Measure Information:
Title
Hepatic glucose release
Description
Hepatic glucose release will be measured by the rate of appearance of a glucose tracer.
Time Frame
Measured up to 4 months from enrollment
Secondary Outcome Measure Information:
Title
Hepatic phosphate concentrations
Description
Hepatic phosphate relative concentrations will be measured with 31 phosphorus magnetic resonance spectroscopy
Time Frame
Measured up to 4 months from enrollment
Title
Rates of lipolysis
Description
Rate of lipolysis will be measured by the rate of appearance of a glycerol tracer.
Time Frame
Measured up to 4 months from enrollment
Title
Hepatic Fat Fraction
Description
Amount of fat in the liver measured by MRI and calculated via the Dixon method as the proton density hepatic fat fraction, which ranges from 0-75%. Greater than 5% is considered extra fat in the liver.
Time Frame
Measured up to 4 months from enrollment
Title
Hepatic de novo lipogenesis
Description
Hepatic de novo lipogenesis will be measured by with an acetate tracer.
Time Frame
Measured up to 4 months from enrollment
Other Pre-specified Outcome Measures:
Title
Whole Body Insulin Sensitivity
Description
Participants will undergo a 75 gram oral glucose tolerance test, and whole body insulin sensitivity will be expressed as Si, calculated via the oral minimal model.
Time Frame
Measured up to 4 months from enrollment
Title
Sleep quality
Description
Apnea Hypopnea Index (AHI) will be measured using WatchPAT. In children and adolescents the scale that will be used is AHI>5 is considered mild sleep apnea. The higher the AHI, indicates more severe sleep apnea.
The AHI is the number of times you have apnea or hypopnea during one night, divided by the hours of sleep.
Normal sleep: An AHI of fewer than five events, on average, per hour Mild sleep apnea: An AHI of five to 14 events per hour Moderate sleep apnea: An AHI of 15 to 29 events per hour Severe sleep apnea: An AHI of 30 or more events per hour
Time Frame
Measured up to 4 months from enrollment
Title
Sleep duration
Description
Sleep duration will be assessed using home actigraphy using the Philips Actigraph wrist-worn watch, and collects 7 days of data.
Time Frame
Measured up to 4 months from enrollment
Title
Stool microbiome profile
Description
Change in expression of stool microbiome species by comparing the PCOS group to samples collected from a control group without PCOS. The 5 species with the most significant will be identified and reported from a Manhattan Plot (% rate of appearance): the values above 0 represent species that are greater in the control group than in PCOS and values below 0 represent species that are greater in PCOS than in the control group.
Time Frame
Measured up to 4 months from enrollment
Title
Amino Acid Metabolomics: glutamate
Description
Targeted amino acid metabolomics will be performed to measure glutamate
Time Frame
Measured up to 4 months from enrollment
Title
Lipid Metabolomics: 16n1
Description
Targeted lipid metabolomics will be performed to measure 16n1
Time Frame
Within 4 months from Screening Visit
Title
Bile Acid Metabolomics: sphingosine-1-phospate
Description
Targeted bile acid metabolomics will be performed to measure sphingosine-1-phospate
Time Frame
Measured up to 4 months from enrollment
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Females
2 years post-menarche
BMI percentile >90%
Exclusion Criteria:
Type 2 diabetes
Anemia
Liver disease
Medications known to effect insulin sensitivity
Cause of oligomenorrhea or hirsutism other than PCOS,
>3 hours a week of moderate exercise.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melanie Cree Green, MD, PhD
Organizational Affiliation
Department of Endocrinology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Anshutz Medical Campus/Children's Hospital Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Data will only be shared with IRB approved personnel.
Citations:
PubMed Identifier
31301251
Citation
Carreau AM, Pyle L, Garcia-Reyes Y, Rahat H, Vigers T, Jensen T, Scherzinger A, Nadeau KJ, Cree-Green M. Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index). Clin Endocrinol (Oxf). 2019 Oct;91(4):544-552. doi: 10.1111/cen.14062. Epub 2019 Aug 16.
Results Reference
derived
PubMed Identifier
30888398
Citation
Simon SL, McWhirter L, Diniz Behn C, Bubar KM, Kaar JL, Pyle L, Rahat H, Garcia-Reyes Y, Carreau AM, Wright KP, Nadeau KJ, Cree-Green M. Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3525-3534. doi: 10.1210/jc.2018-02385.
Results Reference
derived
Learn more about this trial
Liver and Fat Regulation in Overweight Adolescent Girls
We'll reach out to this number within 24 hrs